相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF
Alexander Peikert et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter
Volker Vallon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?
Alexandre O. Gerard et al.
DIABETES CARE (2022)
Cardiovascular Events with Finerenone in CKD and Diabetes
Pei-Heng Kao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
Pierre Delanaye et al.
DIABETES & METABOLISM (2021)
FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease
Giovanna Liuzzo et al.
EUROPEAN HEART JOURNAL (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
Pierpaolo Pellicori et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Forgotten Antiproteinuric Properties of Diuretics
Hernando Trujillo et al.
AMERICAN JOURNAL OF NEPHROLOGY (2021)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
The tubular hypothesis of nephron filtration and diabetic kidney disease
Volker Vallon et al.
NATURE REVIEWS NEPHROLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Jelena P. Seferovic et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
Andrea Kleindienst et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2020)
Tissue sodium content in patients with type 2 diabetes mellitus
Dennis Kannenkeril et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2019)
Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients
Takahiro Masuda et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetes, heart failure, and renal dysfunction: The vicious circles
Eugene Braunwald
PROGRESS IN CARDIOVASCULAR DISEASES (2019)
Hyperkalemia: pathophysiology, risk factors and consequences
Robert W. Hunter et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus
Rabea Asleh et al.
HEART FAILURE REVIEWS (2018)
Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink
Naveed Sattar et al.
CIRCULATION (2018)
SGLT2 inhibition and kidney protection
Josselin Nespoux et al.
CLINICAL SCIENCE (2018)
Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030
Christian Bommer et al.
DIABETES CARE (2018)
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide
Tesshu Takada et al.
NEPHROLOGY (2018)
Diuretic Treatment in Heart Failure
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Milton Packer et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Kevin Damman et al.
JACC-HEART FAILURE (2018)
The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure
Francesco Rossi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Diuretic Treatment in Heart Failure
David H. Ellison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment
Massimo Volpe et al.
CLINICAL SCIENCE (2016)
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016
Murray Epstein et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Pendrin-A New Target for Diuretic Therapy?
Carsten A. Wagner
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
The Role of Pendrin in Renal Physiology
Susan M. Wall et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 77 (2015)
Collecting Duct Intercalated Cell Function and Regulation
Ankita Roy et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine
Mette Staehr et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy
Olivier Moranne et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
Wendy E. Boertien et al.
KIDNEY INTERNATIONAL (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Potentiation of the Effect of Thiazide Derivatives by Carbonic Anhydrase Inhibitors: Molecular Mechanisms and Potential Clinical Implications
Kamyar Zahedi et al.
PLOS ONE (2013)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects Insights From an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) Substudy
Patrick Rossignol et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Diuretic uptitration with half dose combined ACEI plus ARB better decreases proteinuria than combined ACEI plus ARB uptitration
Vincent L. M. Esnault et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications
Alain Doucet et al.
PEDIATRIC NEPHROLOGY (2007)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
Marvin A. Konstam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
The incidence and implications of aldosterone breakthrough
Andrew S. Bomback et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2007)
Pathophysiology of antihypertensive therapy with diuretics
Michio Fukuda et al.
HYPERTENSION RESEARCH (2006)
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents
VLM Esnault et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
KJ Schjoedt et al.
DIABETOLOGIA (2004)
Mechanisms and management of diuretic resistance in congestive heart failure
LKM De Bruyne
POSTGRADUATE MEDICAL JOURNAL (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Vasopressin increases urinary albumin excretion in rats and humans:: involvement of V2 receptors and the renin-angiotensin system
P Bardoux et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack (Vol 358, pg 1033, 2001)
LANCET (2001)
Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung
C Nicco et al.
HYPERTENSION (2001)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
S MacMahon et al.
LANCET (2001)
分享论文
